The University of Chicago Header Logo

Connection

Ravi Salgia to Male

Back to Details
This is a "connection" page, showing publications Ravi Salgia has written about Male.
Ravi Salgia
Connection Strength
1.409
Male
  1. RLIP: A necessary transporter protein for translating oxidative stress into pro-obesity and pro-carcinogenic signaling. Biochim Biophys Acta Rev Cancer. 2022 09; 1877(5):188803.
    View in: PubMed
    Score: 0.045
  2. Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. Clin Lung Cancer. 2022 03; 23(2):e137-e139.
    View in: PubMed
    Score: 0.042
  3. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest. 2021 09; 160(3):1095-1107.
    View in: PubMed
    Score: 0.041
  4. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. Cold Spring Harb Mol Case Stud. 2020 12; 6(6).
    View in: PubMed
    Score: 0.040
  5. Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. Magn Reson Imaging. 2020 06; 69:49-56.
    View in: PubMed
    Score: 0.038
  6. Precision medicine and actionable alterations in lung cancer: A single institution experience. PLoS One. 2020; 15(2):e0228188.
    View in: PubMed
    Score: 0.038
  7. Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
    View in: PubMed
    Score: 0.037
  8. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. Am J Clin Oncol. 2019 04; 42(4):337-344.
    View in: PubMed
    Score: 0.035
  9. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. Eur Urol. 2018 07; 74(1):124-128.
    View in: PubMed
    Score: 0.034
  10. Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy. BMC Cancer. 2018 03 21; 18(1):314.
    View in: PubMed
    Score: 0.033
  11. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.
    View in: PubMed
    Score: 0.033
  12. MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017 04; 16(4):555-565.
    View in: PubMed
    Score: 0.031
  13. A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer. 2017 03; 105:7-13.
    View in: PubMed
    Score: 0.030
  14. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget. 2016 Oct 11; 7(41):66880-66891.
    View in: PubMed
    Score: 0.030
  15. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist. 2016 06; 21(6):762-70.
    View in: PubMed
    Score: 0.029
  16. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86.
    View in: PubMed
    Score: 0.029
  17. Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer. Am J Clin Oncol. 2015 Oct; 38(5):442-7.
    View in: PubMed
    Score: 0.028
  18. The educational impact of the Specialty Care Access Network-Extension of Community Healthcare Outcomes program. Telemed J E Health. 2014 Nov; 20(11):1004-8.
    View in: PubMed
    Score: 0.026
  19. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1666-75.
    View in: PubMed
    Score: 0.025
  20. A new hope for precision medicine. Sci Transl Med. 2013 Oct 23; 5(208):208fs38.
    View in: PubMed
    Score: 0.024
  21. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. Cancer Lett. 2014 Feb 01; 343(1):14-23.
    View in: PubMed
    Score: 0.024
  22. CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer. Am J Respir Crit Care Med. 2012 Nov 15; 186(10):940-1.
    View in: PubMed
    Score: 0.023
  23. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.
    View in: PubMed
    Score: 0.020
  24. Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. J Clin Pathol. 2011 Jan; 64(1):16-24.
    View in: PubMed
    Score: 0.020
  25. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009 Sep 15; 15(18):5714-23.
    View in: PubMed
    Score: 0.018
  26. FYN is overexpressed in human prostate cancer. BJU Int. 2009 Jan; 103(2):171-7.
    View in: PubMed
    Score: 0.017
  27. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007 Apr 15; 67(8):3529-34.
    View in: PubMed
    Score: 0.015
  28. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer. 2006 Nov; 54(2):243-5.
    View in: PubMed
    Score: 0.015
  29. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. Oncologist. 2023 09 07; 28(9):e748-e755.
    View in: PubMed
    Score: 0.012
  30. Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. J Clin Oncol. 2003 Jun 15; 21(12):2437-8.
    View in: PubMed
    Score: 0.012
  31. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003 Feb 15; 21(4):624-30.
    View in: PubMed
    Score: 0.012
  32. Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinases. Methods Mol Med. 2003; 85:87-105.
    View in: PubMed
    Score: 0.012
  33. Intrinsically disordered BMP4 morphogen and the beak of the finch: Co-option of an ancient axial patterning system. Int J Biol Macromol. 2022 Oct 31; 219:366-373.
    View in: PubMed
    Score: 0.011
  34. Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC). Am J Clin Oncol. 2022 02 01; 45(2):49-54.
    View in: PubMed
    Score: 0.011
  35. Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Med. 2022 01; 11(1):21-27.
    View in: PubMed
    Score: 0.011
  36. The Association between Polluted Neighborhoods and TP53-Mutated Non-Small Cell Lung Cancer. Cancer Epidemiol Biomarkers Prev. 2021 08; 30(8):1498-1505.
    View in: PubMed
    Score: 0.010
  37. MicroRNA-1: Diverse role of a small player in multiple cancers. Semin Cell Dev Biol. 2022 04; 124:114-126.
    View in: PubMed
    Score: 0.010
  38. Disparate outcomes in nonsmall cell lung cancer by immigration status. Cancer Med. 2021 04; 10(8):2660-2667.
    View in: PubMed
    Score: 0.010
  39. Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. Clin Lung Cancer. 2021 09; 22(5):e678-e683.
    View in: PubMed
    Score: 0.010
  40. Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. Clin Colorectal Cancer. 2021 06; 20(2):e129-e138.
    View in: PubMed
    Score: 0.010
  41. The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. Clin Lung Cancer. 2021 01; 22(1):e84-e97.
    View in: PubMed
    Score: 0.010
  42. Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2020 05; 19(5):1210-1217.
    View in: PubMed
    Score: 0.009
  43. Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. Cell Commun Signal. 2019 12 16; 17(1):167.
    View in: PubMed
    Score: 0.009
  44. Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. J Clin Pharmacol. 2019 12; 59(12):1632-1640.
    View in: PubMed
    Score: 0.009
  45. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer. 2019 07; 133:136-143.
    View in: PubMed
    Score: 0.009
  46. Early mortality of stage IV non-small cell lung cancer in the United States. Acta Oncol. 2019 Aug; 58(8):1095-1101.
    View in: PubMed
    Score: 0.009
  47. Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol. 2018 10; 41(10):963-966.
    View in: PubMed
    Score: 0.009
  48. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. Semin Oncol. 2018 08; 45(4):210-219.
    View in: PubMed
    Score: 0.008
  49. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 08; 82(2):309-317.
    View in: PubMed
    Score: 0.008
  50. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 05 01; 101(1):177-185.
    View in: PubMed
    Score: 0.008
  51. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep 12; 17(1):646.
    View in: PubMed
    Score: 0.008
  52. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. Oncotarget. 2017 Jun 27; 8(26):42198-42213.
    View in: PubMed
    Score: 0.008
  53. Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. Eur J Oncol Nurs. 2017 Aug; 29:125-134.
    View in: PubMed
    Score: 0.008
  54. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696.
    View in: PubMed
    Score: 0.008
  55. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 09; 15(9):2175-86.
    View in: PubMed
    Score: 0.007
  56. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016 Apr; 27(4):693-9.
    View in: PubMed
    Score: 0.007
  57. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Dec 20; 33(36):4284-92.
    View in: PubMed
    Score: 0.007
  58. Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer. Oncogene. 2016 05 05; 35(18):2357-69.
    View in: PubMed
    Score: 0.007
  59. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6.
    View in: PubMed
    Score: 0.007
  60. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol. 2015 Aug; 26(8):1741-8.
    View in: PubMed
    Score: 0.007
  61. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015 Aug; 5(8):850-9.
    View in: PubMed
    Score: 0.007
  62. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2015 Jul; 89(1):43-9.
    View in: PubMed
    Score: 0.007
  63. c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. Am J Physiol Lung Cell Mol Physiol. 2015 May 15; 308(10):L1025-38.
    View in: PubMed
    Score: 0.007
  64. Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. J Biol Chem. 1995 Mar 10; 270(10):5039-47.
    View in: PubMed
    Score: 0.007
  65. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. Mol Cancer Ther. 2015 Feb; 14(2):461-9.
    View in: PubMed
    Score: 0.007
  66. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242.
    View in: PubMed
    Score: 0.007
  67. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45.
    View in: PubMed
    Score: 0.007
  68. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20; 371(21):1963-71.
    View in: PubMed
    Score: 0.006
  69. Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature. Dis Esophagus. 2015 Nov-Dec; 28(8):772-81.
    View in: PubMed
    Score: 0.006
  70. Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening. J Med Screen. 2014 Dec; 21(4):207-15.
    View in: PubMed
    Score: 0.006
  71. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
    View in: PubMed
    Score: 0.006
  72. Increased µ-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014 Jul; 113 Suppl 1:i103-8.
    View in: PubMed
    Score: 0.006
  73. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
    View in: PubMed
    Score: 0.006
  74. Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis. Int J Med Sci. 2013; 10(8):988-94.
    View in: PubMed
    Score: 0.006
  75. EphB4 as a therapeutic target in mesothelioma. BMC Cancer. 2013 May 30; 13:269.
    View in: PubMed
    Score: 0.006
  76. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Jul; 81(1):138-41.
    View in: PubMed
    Score: 0.006
  77. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol. 2013 Jun 01; 31(16):e254-8.
    View in: PubMed
    Score: 0.006
  78. Altered membrane fluidity in rat hepatocytes during endotoxic shock. Mol Cell Biochem. 1993 Apr 21; 121(2):143-8.
    View in: PubMed
    Score: 0.006
  79. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77.
    View in: PubMed
    Score: 0.006
  80. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013 Jun; 49(6):525-33.
    View in: PubMed
    Score: 0.006
  81. Evidence-based role of bevacizumab in non-small cell lung cancer. Ann Oncol. 2013 Jan; 24(1):6-9.
    View in: PubMed
    Score: 0.006
  82. Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. PLoS One. 2012; 7(9):e45330.
    View in: PubMed
    Score: 0.006
  83. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012 Oct; 13(10):1011-9.
    View in: PubMed
    Score: 0.006
  84. Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg. 2012 Oct; 94(4):1086-92.
    View in: PubMed
    Score: 0.006
  85. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol. 2012 May; 7(5):856-65.
    View in: PubMed
    Score: 0.005
  86. Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012 Apr; 116(4):857-67.
    View in: PubMed
    Score: 0.005
  87. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer. 2012 Feb 28; 106(5):839-45.
    View in: PubMed
    Score: 0.005
  88. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
    View in: PubMed
    Score: 0.005
  89. Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. Int Surg. 2012 Jan-Mar; 97(1):65-70.
    View in: PubMed
    Score: 0.005
  90. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
    View in: PubMed
    Score: 0.005
  91. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011 Dec 20; 29(36):4803-10.
    View in: PubMed
    Score: 0.005
  92. Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. Biochem J. 2011 Oct 01; 439(1):45-55.
    View in: PubMed
    Score: 0.005
  93. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5.
    View in: PubMed
    Score: 0.005
  94. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012 Jan; 39(1):27-38.
    View in: PubMed
    Score: 0.005
  95. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011 Oct; 12(11):1004-12.
    View in: PubMed
    Score: 0.005
  96. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25.
    View in: PubMed
    Score: 0.005
  97. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011 Aug 15; 17(16):5257-67.
    View in: PubMed
    Score: 0.005
  98. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):446-50.
    View in: PubMed
    Score: 0.005
  99. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
    View in: PubMed
    Score: 0.005
  100. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. J Thorac Oncol. 2011 Apr; 6(4):786-9.
    View in: PubMed
    Score: 0.005
  101. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res. 2011 May 15; 17(10):3112-22.
    View in: PubMed
    Score: 0.005
  102. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
    View in: PubMed
    Score: 0.005
  103. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010 May 20; 28(15):2598-603.
    View in: PubMed
    Score: 0.005
  104. Fyn: a novel molecular target in cancer. Cancer. 2010 Apr 01; 116(7):1629-37.
    View in: PubMed
    Score: 0.005
  105. The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. Aliment Pharmacol Ther. 2010 Mar; 31(6):625-33.
    View in: PubMed
    Score: 0.005
  106. Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. Arch Pathol Lab Med. 2008 Dec; 132(12):1882-8.
    View in: PubMed
    Score: 0.004
  107. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
    View in: PubMed
    Score: 0.004
  108. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15; 113(4):808-14.
    View in: PubMed
    Score: 0.004
  109. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1104-10.
    View in: PubMed
    Score: 0.004
  110. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J Clin Oncol. 2008 Feb 20; 26(6):870-6.
    View in: PubMed
    Score: 0.004
  111. Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. Am J Clin Oncol. 2007 Jun; 30(3):258-63.
    View in: PubMed
    Score: 0.004
  112. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):515-22.
    View in: PubMed
    Score: 0.004
  113. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5880-7.
    View in: PubMed
    Score: 0.003
  114. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002 Jun 01; 53(2):394-400.
    View in: PubMed
    Score: 0.003
  115. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol. 2001 Aug; 48(2):151-9.
    View in: PubMed
    Score: 0.003
  116. Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med. 1989 Sep; 149(9):1959-61.
    View in: PubMed
    Score: 0.001
  117. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol. 1987 Dec; 5(12):1998-2003.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.